Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital;Étude de la sensibilité aux antibiotiques de souches cliniques de Clostridium difficile isolées de 2001 à 2007 au CHU Henri-Mondor, Créteil

Pathologie Biologie

Volumn 56, Issue 7-8, 2008, Pages 407-411

  Cattoir, V ^a   Ould Hocine, Z F ^a   Legrand, P ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Antibiogram; C. difficile; In vitro activity; Resistance; Susceptibility

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COLISTIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; METRONIDAZOLE; OFLOXACIN; PENICILLIN G; PRISTINAMYCIN; RIFAMPICIN; SPIRAMYCIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISK DIFFUSION; DRUG ACTIVITY; DRUG SCREENING; FRANCE; HUMAN; IN VITRO STUDY; INFORMATION PROCESSING; NONHUMAN; UNIVERSITY HOSPITAL; COMPARATIVE STUDY; CROSS INFECTION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMEMBRANOUS COLITIS; STATISTICS;

CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 57049152891     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.07.022     Document Type: Article

References (20)

1. Hall J., and O'Toole. Intestinal flora in newborn infants with description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis 49 (1935) 390-402
2. Blanckaert K., Coignard B., Grandbastien B., Astagneau, and Barbur F. Actualités sur les infections à Clostridium difficile. Rev Med Int 29 (2008) 209-214
3. Barbut F. Infections à Clostridium difficile : une réémergence inattendue. Pathol Biol 56 (2008) 6-9
4. Owens Jr. R.C., Donskey C.J., Gaynes R.P., Loo V.G., and Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46 Suppl. 1 (2008) 19-31
5. Barbut F., Delmée M., Brazier J.S., Petit J.C., Poxton I.R., Rupnik M., et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 9 (2003) 989-996
6. Mory F., Lozniewski A., Bland S., Sedallian A., Grollier G., Girard-Pipau F., et al. Survey of anaerobic susceptibility patterns: a French multicentre study. Int J Antimicrob Agents 10 (1998) 229-236
7. Barbut F., Decre D., Burghoffer B., Lesage D., Delisle F., Lalande V., et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 43 (1999) 2607-2611
8. Jamal W.Y., Mokaddas E.M., Verghese T.L., and Rotimi V.O. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 20 (2002) 270-274
9. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y., Tyrrell K., and Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob Agents Chemother 47 (2003) 1968-1971
10. Aspevall O., Lundberg A., Burman L.G., Akerlund T., and Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 50 (2006) 1890-1892
11. Bourgault A.M., Lamothe F., Loo V.G., and Poirier L. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in southern Quebec, Canada. Antimicrob Agents Chemother 50 (2006) 3473-3475
12. Bishara J., Bloch Y., Garty M., Behor J., and Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 54 (2006) 141-144
13. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., and Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51 (2007) 2716-2719
14. Pelaez T., Alcala L., Alonso R., Rodriguez-Creixems M., Garcia-Lechuz J.M., and Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46 (2002) 1647-1650
15. Chow A.W., Cheng N., and Bartlett K.H. In vitro susceptibility of Clostridium difficile to new β-lactam and quinolone antibiotics. Antimicrob Agents Chemother 28 (1985) 842-844
16. Freeman J., Baines S.D., Jabes D., and Wilcox M.H. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 56 (2005) 717-725
17. Bendle J.S., James P.A., Bennett P.M., Avison M.B., Macgowan A.P., and Al-Shafi K.M. Resistance determinants in strains of Clostridium difficile from two geographically distinct populations. Int J Antimicrob Agents 24 (2004) 619-621
18. John R., and Brazier J.S. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 61 (2005) 11-14
19. Levett P.N. Antimicrobial susceptibility of Clostridium difficile determined by disc diffusion and breakpoint methods. J Antimicrob Chemother 22 (1988) 167-173
20. Schmidt C., Loffler B., and Ackermann G. Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn Microbiol Infect Dis 59 (2007) 1-5